Glycemic Control Continues to Deteriorate After Sulfonylureas Are Added to Metformin Among Patients With Type 2 Diabetes
Authors:
Open Access
- 1 May 2005
- journal article
- research article
- Published by American Diabetes Association in Diabetes Care
- Vol. 28 (5) , 995-1000
Abstract
OBJECTIVE—To describe the course and predictors of glycemic control among patients with type 2 diabetes after sulfonylureas (SUs) are added to metformin (MF). RESEARCH DESIGN AND METHODS—Patients (n = 2,220) treated with MF monotherapy for >90 days before initiating MF plus SU combination therapy between January 1998 and March 2004 were studied in a retrospective analysis of electronic medical records from U.K. primary care practices using the General Practice Research Database. Median glycoslyated hemoglobin A1c (A1C) before and after SU initiation was described, and patient characteristics were evaluated as predictors of time until A1C ≥8.0% or glucose-lowering therapy was intensified (by starting insulin or adding a third oral agent). RESULTS—At 6 months post-SU initiation, median A1C resumed deteriorating at a somewhat comparable rate to that observed on MF monotherapy. Higher pre-SU A1C, younger age, female sex, shorter diabetes duration, higher serum creatinine, and being an ex-smoker predicted time until A1C ≥8.0% or glucose-lowering therapy was intensified in various analyses. Median A1C was 9.5% when therapy was intensified. A1C ≥8.0% was estimated to occur in 85% of patients 4 years after SU initiation and in 68% 4 years after initially achieving A1C <7% on MF plus SU therapy. CONCLUSIONS—In this population, glycemic control is improved following the addition of SUs to MF, but deterioration resumes as early as 6 months. The high proportion of patients remaining on MF plus SU therapy despite having A1C ≥8.0% suggests that there are significant barriers to starting insulin or adding a third agent when treatment goals are not achieved with this combination.Keywords
This publication has 22 references indexed in Scilit:
- Sustained effects of pioglitazone vs. glibenclamide on insulin sensitivity, glycaemic control, and lipid profiles in patients with Type 2 diabetesDiabetic Medicine, 2004
- Standards of Medical Care in DiabetesDiabetes Care, 2004
- Economic Costs of Diabetes in the U.S. in 2002Diabetes Care, 2003
- Safety and patient tolerance of standard and slow-release formulations of NSAIDsPharmacoepidemiology and Drug Safety, 2003
- Coefficient of failure: a methodology for examining longitudinal β‐cell function in Type 2 diabetesDiabetic Medicine, 2002
- Sulfonylurea InadequacyDiabetes Care, 2002
- Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33)The Lancet, 1998
- Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34)The Lancet, 1998
- U.K. prospective diabetes study 16. Overview of 6 years' therapy of type II diabetes: a progressive disease. U.K. Prospective Diabetes Study GroupDiabetes, 1995
- Secondary failure of oral hypoglycaemic agents: Frequency, possible causes, and managementDiabetes/Metabolism Research and Reviews, 1994